Copanlisib plus Gemcitabine Has Efficacy in Peripheral T-cell Lymphomas. 2021


A phase I/II trial demonstrated a response rate of 72% in patients with relapsed or refractory disease.

UI MeSH Term Description Entries

Related Publications

No sufficiently related or similar publications found.

Copied contents to your clipboard!